What challenges did IQVIA face before AI implementation?

Manual and repetitive tasks consuming employee time in pharmaceutical workflows. Bias in clinical trials, leading to incomplete safety profiling and limited demographic representation. Lack of technological tools to optimize productivity and strategic focus for employees. Potential risks associated with the use of generative AI in sensitive fields like life sciences.

What was the impact of the AI solution?

Employees spend more time on strategic tasks and less on repetitive workflows. Improved employee satisfaction and retention through strategic task focus. Increased transparency and safety in clinical trials by addressing demographic biases. Boosted overall productivity and operational efficiency in pharmaceutical workflows.

Source

MicrosoftLive source

IQVIA revolutionizes pharmaceutical processes with AI and Microsoft

Updated Jun 13, 2026

This case highlights the collaboration between IQVIA, a healthcare and pharma clinical research company, and Microsoft, focusing on embedding AI technologies, including generative AI, into pharmaceutical workflows. AI solutions were adapted specifically for life sciences, notably transforming workflows by automating mundane tasks, enabling employees to focus on strategic efforts. Crucially, these implementations maintained risk mitigation oversight while addressing biases in clinical trials and enhancing employee productivity. AI's ability to enhance productivity, drive patient outcomes, and uncover biases in trial data has made it a transformative tool in the industry, demonstrating its potential to reshape operations profoundly.

Organization: IQVIA
Industry: Pharma
Location: United States
Published: January 2024

Reported outcomes

Strategic outcomes

Speed & agilityAutomated manual pharmaceutical workflowsEmployee experienceEnabled focus on strategic workRisk & complianceImproved clinical trial bias detectionCustomer experience & trustEnhanced clinical trial transparency and safety

Primary read

Use case focus

Showing 3 of 3

1clinical trial bias detection
2employee productivity assistance
3safety profiling

Manual and repetitive tasks consuming employee time in pharmaceutical workflows.
Bias in clinical trials, leading to incomplete safety profiling and limited demographic representation.
Lack of technological tools to optimize productivity and strategic focus for employees.
Potential risks associated with the use of generative AI in sensitive fields like life sciences.

Implemented AI, including generative AI, to automate data mining and other manual workflows.
Used Microsoft's AI capabilities as a 'copilot' to assist employees in improving productivity.
Applied AI tools to uncover and mitigate biases during pharmaceutical clinical trials.
Ensured human oversight in generative AI processes to avoid risks and ensure safety.

Technologies

Azure AI Copilot

Employees spend more time on strategic tasks and less on repetitive workflows.
Improved employee satisfaction and retention through strategic task focus.
Increased transparency and safety in clinical trials by addressing demographic biases.
Boosted overall productivity and operational efficiency in pharmaceutical workflows.

Architecture

The implementation integrated Microsoft's generative AI capabilities as a copilot into IQVIA's workflows. AI-powered tools automated repetitive tasks and enabled employee focus on strategic roles, with data analysis for clinical trial biases ensuring comprehensive demographic safety profiling.

Sources & evidence1

Live sourceStill referenced

The case's original source is still reachable.